Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025

Skye Bioscience, Inc.

2025-Q2 EPS reported -$0.72

Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
Cash, equivalents & short-term investments $48.6M as of June 30, 2025; expected to fund operations through at least Q1 2027.
Phase 2a CBeyond study of nimacimab top-line data expected late Q3/early Q4 2025; extension study enrolling.
Preclinical data: nimacimab + low-dose tirzepatide boosted weight loss beyond optimal tirzepatide; nimacimab reduced post-treatment weight rebound.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.